Method of visualizing a bridge therapy process

Patent metadata

Field	Value
Publication number	US-9788798-B2
Application number	US-201214126545-A
Country	US
Kind code	B2
Filing date	Jun 12, 2012
Priority date	Jun 16, 2011
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

The present invention provides for a simultaneous graphical representation, a risk of bleeding and a risk of thrombosis providing a visualized bridge therapy process. Furthermore, the present invention provides for a computer-based prediction of the haemostatic situation of the examined blood circulation by using a combination of a biochemical model and a pharmacokinetic model for calculation or another mathematical representation of the blood circulation.

First claim

The invention claimed is:

1. A method of visualizing a bridge therapy process, the method comprising the steps of:
receiving coagulation data describing a haemostatic situation of a blood circulation of a patient at a computer having a processor and a display, and
displaying, on the display of the computer, the coagulation data to a user by means of a graphical representation, the displaying including:
displaying a first value measured by a first type of blood test, wherein the first value indicates a first effect of a heparin like drug on the haemostatic situation, and
simultaneously to the displaying of the first value displaying a second value measured by a second type of blood test, wherein the second value indicates a second effect of a vitamin K antagonist type anticoagulant on the haemostatic situation, and
wherein the first and second values describe the haemostatic situation of the blood circulation at a first point in time and are simultaneously displayed as a first point within an X and Y coordinate system having the first value for the X axis and the second value for the Y axis.

2. The method according to claim 1 , the displaying of the coagulation data further comprising the steps of:
displaying, on the display of the computer, a third value measured by the first type of blood test, wherein the third value indicates a third effect of a heparin like drug on the haemostatic situation,
simultaneously to the displaying of the third value displaying, on the display of the computer, a fourth value measured by the second type of blood test, wherein the fourth value indicates a fourth effect of a vitamin K antagonist type anticoagulant on the haemostatic situation,
wherein the third and fourth values describe the haemostatic situation of the blood circulation at a second point in time and are simultaneously displayed as a second point within the X and Y coordinate system having the third value for the X axis and the fourth value for the Y axis.

3. The method according to claim 1 , wherein the first and second type of blood test are respectively and independently chosen from the group consisting of activated partial thrombopiastine time (aPTT) test, anti-Factor 10a test, prothrombin time (PT) test, international normalized ratio (INR) test, a test indicating thrombosis or coagulation, a test indicating bleeding or anti-coagulation, a test indicating the haemostatic function.

4. The method according to claim 1 , further comprising the step of:
calculating, using the processor of the computer, a prediction of the haemostatic situation of the blood circulation by a mathematical representation of the blood circulation.

5. The method according to claim 1 , further comprising the step of:
calculating, using the processor of the computer, a prediction of the haemostatic situation of the blood circulation by combining a biochemical model of the blood circulation and a pharmacodynaniical model of the blood circulation.

6. The method according to claim 5 , further comprising the steps of:
calculating, using the processor of the computer, an effect of an anticoagulant drug during a predetermined time by using the pharmacodynamical model, to generate a calculated pharmacodynamical effect.

7. The method according to claim 6 , the method further comprising the steps of:
calculating, using the processor of the computer, a coagulation effect and/or a fibrin polymerization effect with the biochemical model based on the calculated pharmacodynamical effect, and
displaying, on the display of the computer, a prediction value of the haemostatic situation,
wherein the prediction value is based on at least one of the calculated pharmacodynamical effect, the calculated coagulation effect, and the calculated fibrin polymerization effect.

8. The method according to claim 1 , the method further comprising the step of:
automatically suggesting an application of a coagulant and/or an anti-coagulant.

9. The method according to claim 8 , wherein the step of automatically suggesting an application of a coagulant and/or an anti-coagulant is based on a calculated progression of the haemostatic situation.

10. The method of claim 1 further comprising the step of:
displaying a rectangle in the X and Y coordinate system depicting a region in which a safe haemostatic situation is indicated.

11. A user interface device for visualizing a bridge therapy process, the user interface comprising:
a user interface configured to receive coagulation data describing a haemostatic situation of a blood circulation of a patient,
a display configured to display the haemostatic situation of said blood circulation including:
displaying a first value measured by a first type of blood test, wherein the first value indicates a first effect of a heparin like drug on the haemostatic situation, and
simultaneously displaying a second value measured by a second type of blood test, wherein the second value indicates a second effect of a vitamin K antagonist type anticoagulant on the haemostatic situation;
wherein the first and second values describe the haemostatic situation of the blood circulation at a first point in time; and
wherein the first and second values are simultaneously displayed as the first point within a two-dimensional coordinate system having an axis for the first type of blood test and a different axis for the second type of blood test.

12. The user interface device according to claim 11 wherein the user interface is configured to display a time progression of the haemostatic situation of said blood circulation by further:
displaying a third value measured by the first type of blood test, wherein the third value indicates a third effect of a heparin like drug on the haemostatic situation at a second point in time, and
displaying a fourth value measured by the second type of blood test simultaneously to the first, second and third value, wherein the fourth value indicates a fourth effect of a vitamin K antagonist type anticoagulant on the haemostatic situation at the second point in time, and
wherein the third and fourth values describe the haemostatic situation of the blood circulation at the second point in time.

13. The user interface device according to claim 11 , further comprising:
a computer processor configured to calculate a prediction of the haemostatic situation of the blood circulation by using mathematical representation of the blood circulation or by a combining a biochemical model of the blood, circulation and a pharmacodynamical model of the blood circulation.

14. The user interface device according to claim 11 , wherein the computer processor is configured to:
calculate an effect of an anticoagulant drug during a predetermined time by using the pharmacodynamical model,
generate a calculated pharmacodynamical effect, and
use the calculated pharmacodynamical effect as an input for the biochemical model.

15. The user interface device of claim 11 wherein the display is configured to further display a rectangle in the two-dimensional coordinate system depicting a region in which a safe haemostatic situation is indicated.

16. A non-transitory computer readable medium in which a program element for visualizing a bridge therapy process is stored, which, when being executed by a computer including a processor and a display performs a method including:
receiving coagulation data describing a haemostatic situation of a blood circulation including at least:
a first value measured at a first point in time by a first type of blood test that indicates an effect of a heparin like drug on the haem

Assignees

• Van Ooijen Henk Jan
• Van Den Ham Rene
• Bakker Bart
• Koninklijke Philips Nv

Inventors

• Van Ooijen Henk Jan
• Van Den Ham Rene
• Bakker Bart

Classifications

• A61B5/7475

  User input or interface means, e.g. keyboard, pointing device, joystick · CPC title

• G16B5/30

  Dynamic-time models · CPC title

• A61B5/742

  using visual displays (displays for heart-related electrical signals, e.g. ECG, A61B5/339) · CPC title

• G16H40/60

  for the operation of medical equipment or devices · CPC title

• A61B5/7278

  Artificial waveform generation or derivation, e.g. synthesizing signals from measured signals · CPC title